Clinical trial
ISIS 2302-CS27, A 6-Week, Placebo-Controlled Clinical Study to Evaluate the…
NCT00063830 · Ionis Pharmaceuticals, Inc., Industry · Completed
Key facts
| NCT number | NCT00063830 |
|---|---|
| Title | ISIS 2302-CS27, A 6-Week, Placebo-Controlled Clinical Study to Evaluate the Effectiveness of Alicaforsen (ISIS 2302) in Patients With Mild to Moderate Active Ulcerative Colitis. |
| Official title | ISIS 2302-CS27, Phase 2, Double-Blinded, Controlled Study of Four Dosing Regimens of Alicaforsen (ISIS 2302) Enema, an Antisense Inhibitor of ICAM-1, for the Treatment of Patients With Mild to Moderate Active Ulcerative Colitis |
| Lead sponsor | Ionis Pharmaceuticals, Inc., Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Ulcerative Colitis |
| Intervention type | Drug |
| Interventions | Alicaforsen |
| Start date | Apr 3, 2003 |
| Primary completion | Oct 11, 2004 |
| Completion | Oct 11, 2004 |
| First posted | Jul 8, 2003 |
| Last update posted | Dec 5, 2022 |
| Countries | United States |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: